 | • レポートコード：STR-DC019 • 出版社/出版日：Straits Research / 2019年11月28日 • レポート形態：英文、PDF、136ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：製薬 |
| Single User（1名様用、印刷不可） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User（5名様用） | ￥836,200 (USD5,650) | ▷ お問い合わせ |
| Enterprise Price（法人閲覧用） | ￥1,073,000 (USD7,250) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートでは、糖尿病性ケトアシドーシスの世界市場について調査・分析し、調査手法、市場概要、種類別（インスリン療法、流体補充、電解質補充）分析、エンドユーザー別（病院＆クリニック、外来センター、専門クリニック）分析、地域別分析、企業概要などを含め次の構成でお届け致します。 ・イントロダクション ・調査手法 ・市場概要 ・糖尿病性ケトアシドーシスの世界市場：種類別（インスリン療法、流体補充、電解質補充） ・糖尿病性ケトアシドーシスの世界市場：エンドユーザー別（病院＆クリニック、外来センター、専門クリニック） ・糖尿病性ケトアシドーシスの世界市場：地域別 ・企業概要 |
Global diabetic ketoacidosis treatment market was valued at USD 1,159.54 million in 2018, growing at a CAGR of 5.6% during the forecast period of 2019–2026.
Diabetic ketoacidosis (DKA) is a serious hyperglycemic emergency in people with diabetes. In this complication, body starts to run out of insulin and produces high level of ketones. As a result, DKA changes chemical balance of blood and can lead to death if not treated on time. It mainly affects people with type 1 diabetes. The condition is triggered either by illness or mismanaged insulin doses and can be treated by using fluids, electrolyte, and insulin therapy. In addition, it can be prevented by monitoring blood sugar level and proper insulin dosage regularly. As per the UK National Diabetes report, around 4% of people suffering from type I diabetes develop DKA. To cover the condition, monitored delivery of intravenous fluids and insulins is provided. Replacing fluid loss, decreasing blood glucose, and reversing acidosis are the main priorities of the care. In addition, unregulated insulin dosages are one of the major causes that lead to DKA. As per the National Pediatric Diabetes Audit 2017, 27% increased risk of admission of Diabetic Ketoacidosis Treatment are associated with insulin pumps than the insulin injections.
Increasing Prevalence of Diabetic Ketoacidosis with Type 1 Diabetes
People with diabetes require access to systematic, regular, and organized healthcare from skilled providers. Diabetic ketoacidosis mainly occurs in patients having type 1 diabetes. Despite advancements in self-care of patients with diabetes, DKA is a life-threatening complication and affects around 30 million people in the U.S. In addition, studies have reported that patients that use insulin pumps are more prone to develop DKA and it is more common in young children and adolescents suffering from type 1 diabetes. Almost 50% of diabetes-related admissions in the young population are related to DKA. There has been a rise in cases of DKA with diabetes. As per the CDC report, 168,000 cases were reported for diabetic ketoacidosis in 2014.
Segmental Insights
For a better understanding of the global diabetic ketoacidosis treatment market, we have segmented the market by type, and end user.
By type, the market is segmented into fluid replacement, electrolyte replacement and insulin therapy. Insulin therapy is accounting for the major market share, growing at a CAGR of 5.9% in the forecast period. Insulin reverses the processes that cause excessive ketones to be released in the blood. Along with the fluids and electrolytes, insulin therapy is provided in diabetic ketoacidosis. However, it is administrated after fluid replacement. Whereas, electrolytes are required for proper functioning of tissue. The absence of insulin during diabetic ketoacidosis can lower the level of several electrolytes in the blood. In case of hypokalemia, fluids and potassium replacement is advised before starting insulin because the insulin administration may drop potassium level further.
Regional Insights
Global diabetic ketoacidosis treatment market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is dominating the market and accounted for the highest share in the forecast period. Diabetes and its various related complications such as diabetic ketoacidosis (DKA) put an economic burden on people. It has been observed that the prevalence of DKA is increasing in the patients having type 1 diabetes in the U.S. For instance, National Diabetes Statistics has estimated that about 168,000 cases were diagnosed with diabetic ketoacidosis in 2017. Higher healthcare expenditure and strong penetration of insurance policies covering diabetes and its complications are fueling the market growth. As per the American Diabetes Association, the total cost of diagnosed diabetes reached USD 327 billion in 2017 from USD 245 billion in 2012, out of which around 67.3% cost is covered by the government insurance.
Europe is the second leading region in the forecast period owing to poor diabetic management. Poor diabetic control is one of the major factors responsible for increased risk of diabetic ketoacidosis in the region. This is followed by the use of insulin pumps, which further increases the rate of hospitalization in patients with DKA. As per Diabetes UK, around 2,200 people suffered from diabetic ketoacidosis (DKA) as a result of insulin treatment in 2017. Increasing diabetes-related admissions of children and young people are also increasing cases related to its complications. For instance, during 2014–2015, approximately 40% of DKA admissions were observed within a year of diabetes diagnosis in the U.K.
Key Players
Some of the prominent players in the market are Novo Nordisk and Biocon. Diabetic ketoacidosis treatment market has very few players. Novo Nordisk and Biocon are two major players providing treatment for the indication. For instance, Biocon offers Human Insulin, which is used for treating of type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic ketoacidosis, and other associated indications. It involves the use of two types of insulin once or many times in a day depending on the condition.
TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Diabetic Ketoacidosis Treatment Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
4 Type Overview
4.1 Introduction
4.1.1 Market Size & Forecast
4.2 Insulin Therapy
4.3 Fluid Replacement
4.4 Electrolyte Replacement
5 End User Overview
5.1 Introduction
5.1.1 Market Size & Forecast
5.2 Hospitals & Clinics
5.3 Ambulatory centers
5.4 Specialty Clinics
6 Regional Overview
6.1 Introduction
6.1.1 Market Size & Forecast
6.2 America
6.2.1 North America
6.2.1.1 U.S.
6.2.1.1.1 By Type
6.2.1.1.2 By End User
6.2.1.2 Canada
6.2.1.2.1 By Type
6.2.1.2.2 By End User
6.2.1.3 Mexico
6.2.1.3.1 By Type
6.2.1.3.2 By End User
6.2.2 South America
6.2.2.1 By Type
6.2.2.2 By End User
6.3 Europe
6.3.1 Market Size & Forecast (Value)
6.3.2 Western Europe
6.3.2.1 Germany
6.3.2.1.1 By Type
6.3.2.1.2 By End User
6.3.2.2 France
6.3.2.2.1 By Type
6.3.2.2.2 By End User
6.3.2.3 U.K.
6.3.2.3.1 By Type
6.3.2.3.2 By End User
6.3.2.4 Italy
6.3.2.4.1 By Type
6.3.2.4.2 By End User
6.3.2.5 Spain
6.3.2.5.1 By Type
6.3.2.5.2 By End User
6.3.2.6 Rest of Western Europe
6.3.2.6.1 By Type
6.3.2.6.2 By End User
6.3.3 Eastern Europe
6.4 Asia Pacific
6.4.1 Market Size & Forecast (Value)
6.4.2 China
6.4.2.1 By Type
6.4.2.2 By End User
6.4.3 India
6.4.3.1 By Type
6.4.3.2 By End User
6.4.4 Japan
6.4.4.1 By Type
6.4.4.2 By End User
6.4.5 South Korea
6.4.5.1 By Type
6.4.5.2 By End User
6.4.6 Australia
6.4.6.1 By Type
6.4.6.2 By End User
6.4.7 Rest of Asia-Pacific
6.4.7.1 By Type
6.4.7.2 By End User
6.5 Middle East
6.5.1 Market Size & Forecast (Value)
6.5.2 The Middle East
6.5.2.1 UAE
6.5.2.2.1 By Type
6.5.2.2.2 By End User
6.5.2.2 Qatar
6.5.2.2.1 By Type
6.5.2.2.2 By End User
6.5.2.3 Rest of Middle East
6.5.2.3.1 By Type
6.5.2.3 2 By End User
6.6 Africa
6.6.1 Market Size & Forecast (Value)
6.6.2 South Africa
6.6.2.1 South Africa
6.6.2.1.1 By Type
6.6.2.1.2 By End User
6.6.2.2 Ghana
6.6.2.2.1 By Type
6.6.2.2.2 By End User
6.6.2.3 Nigeria
6.6.2.3.1 By Type
6.6.2.3.2 By End User
6.6.2.4 Rest of Africa
6.6.2.4.1 By Type
6.6.2.4 2 By End User
7. Company Profile
7.1 Novo Nordisk
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Recent Developments
7.1.4 Product Portfolio
7.2 Biocon
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Recent Developments
7.2.4 Product Portfolio
TABLE 1 Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 2 Insulin Therapy Diabetic Ketoacidosis Treatment Market Share, By Region, 2016-2026 ($ Million)
TABLE 3 Fluid Replacement Diabetic Ketoacidosis Treatment Market Share, By Region, 2016-2026, ($ Million)
TABLE 4 Diabetic Ketoacidosis Treatment Market Share Value, 2016-2026 ($Million)
TABLE 5 Diabetic Ketoacidosis Treatment Market Share, By Region, 2016-2026 ($ Million)
TABLE 6 America Diabetic Ketoacidosis Treatment Market Share Value, By Region, 2016-2026 ($Million)
TABLE 7 America Diabetic Ketoacidosis Treatment Market Share value, By Type, 2016-2026 ($Million)
TABLE 8 America Diabetic Ketoacidosis Treatment Market Share value, By End User, 2016-2026 ($Million)
TABLE 9 U.S. Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 10 U.S. Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 11 Canada Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 12 Canada Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 13 Mexico Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 14 Mexico Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 15 South America Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 16 South America Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 17 Europe Diabetic Ketoacidosis Treatment Market Share Value, By Region, 2016-2026 ($Million)
TABLE 18 Europe Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 19 Europe Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 20 Western Europe Diabetic Ketoacidosis Treatment Market Share Value, By Country, 2016-2026 ($Million)
TABLE 21 Western Europe Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 22 Western Europe Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 23 Germany Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 24 Germany Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 25 France Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 26 France Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 27 UK Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 28 UK Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 29 Italy Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 30 Italy Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 31 Spain Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 32 Spain Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 33 Rest of Western Europe Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 34 Rest of Western Europe Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 35 Eastern Europe Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 36 Eastern Europe Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 37 Asia-Pacific Diabetic Ketoacidosis Treatment Market Share, By Country, 2016-2026 ($Million)
TABLE 38 Asia-Pacific Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 39 Asia-Pacific Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 40 Japan Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 41 Japan Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 42 China Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 43 China Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 44 Australia Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 45 Australia Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 46 India Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 47 India Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 48 South Korea Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 49 South Korea Diabetic Ketoacidosis Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 50 Rest of Asia-pacific Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 51 Rest of Asia-pacific Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 52 The Middle East and Africa Diabetic Ketoacidosis Treatment Market Share, By Region, 2016-2026 ($Million)
TABLE 53 The Middle East and Africa Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 54 The Middle East and Africa Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 55 The Middle East Diabetic Ketoacidosis Treatment Market Share, By Country, 2016-2026 ($Million)
TABLE 56 The Middle East Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 57 The Middle East Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 58 Saudi Arabia Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 59 Saudi Arabia Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 60 UAE Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 61 UAE Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 62 Qatar Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 63 Qatar Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 64 Africa Diabetic Ketoacidosis Treatment Market Share, By Country, 2016-2026 ($Million)
TABLE 65 Africa Diabetic Ketoacidosis Treatment Market Share, By Type, 2016-2026 ($Million)
TABLE 66 Africa Diabetic Ketoacidosis Treatment Market Share, By End User, 2016-2026 ($Million)
List of Figures
FIGURE 1 Diabetic Ketoacidosis Treatment Market Overview
FIGURE 2 Value Chain Analysis
FIGURE 3 Bargaining Power of Suppliers
FIGURE 4 Bargaining Power of Buyers
FIGURE 5 Threat of Substitutes
FIGURE 6 Threat of New Entrants
FIGURE 7 Competitive Rivalry
FIGURE 8 Diabetic Ketoacidosis Treatment Market, 2016-2026
FIGURE 9 U.S. Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 10 Canada Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 11 Mexico Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 12 South America Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 13 Western Europe Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 14 Germany Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 15 France Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 16 UK Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 17 Italy Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 18 Spain Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 19 Rest of Western Europe Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 20 Eastern Europe Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 21 Japan Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 22 China Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 23 Australia Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 24 India Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 25 South Korea Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 26 Rest of Asia-pacific Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 27 The Middle East Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 28 Saudi Arabia Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 29 UAE Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 30 Qatar Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 31 Rest of The Middle East Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 32 Africa Diabetic Ketoacidosis Treatment Market Share, 2016-2026 ($Million)
FIGURE 33 Novo Nordisk: Revenue Analysis, ($ million)
FIGURE 34 Novo Nordisk: Segment Revenue 2018 (%)